[Pimecrolimus and vaccinations].
Schmutz
J L
JL
Barbaud
A
A
Tréchot
P
P
D000279:Administration, Cutaneous; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004168:Diphtheria Toxoid / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007223:Infant; D008458:Measles Vaccine / Q000276:immunology; D011446:Prospective Studies; D012411:Rubella Vaccine / Q000276:immunology; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013745:Tetanus Toxoid / Q000276:immunology; D014611:Vaccination
D003879:Dermatologic Agents; D004168:Diphtheria Toxoid; D007166:Immunosuppressive Agents; D008458:Measles Vaccine; D012411:Rubella Vaccine; D013745:Tetanus Toxoid; C117268:pimecrolimus; D016559:Tacrolimus